BOSTON and CHESTERFIELD, Mo., Sept. 24,
2024 /PRNewswire/ -- Today, Ginkgo Bioworks
(NYSE: DNA), which is building the leading platform for cell
programming and biosecurity, announced its new partnership with
NOVUS International, an innovator and leader in intelligent
nutrition, to develop advanced feed additives designed to meet the
evolving needs of the animal agriculture industry. By utilizing
Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more
efficient enzymes that can be produced cost-effectively.
With the agricultural sector facing heightened volatility,
including rising feed costs and tightening margins, NOVUS is
committed to supporting its customers by optimizing the health and
performance of livestock. This partnership aims to bring
cutting-edge technologies to market, enhancing the sustainability
and efficiency of animal production systems. These innovations are
intended to improve the overall well-being of chickens, pigs, and
cows, thereby supporting producers in delivering nutritious and
affordable animal products to consumers.
Abishek Shingote, Associate VP of Global Strategic Marketing,
Technology, and Innovation at NOVUS, highlighted the partnership's
potential: "With the challenges and volatility facing the
agriculture industry, a multifactorial approach is needed for
producers to meet their financial goals and end customers to
continue to enjoy nutritious and affordable meat, milk, and eggs.
This multifactorial approach requires advanced technologies
combined with application knowledge. The partnership with Ginkgo
Bioworks puts NOVUS on the path to create innovative technologies
that support health and performance consistency in chickens, pigs,
and cows. The products we're working to develop came out of
conversation with NOVUS customers and deep analysis of industry
needs. Innovation is at the heart of NOVUS. Sustaining thriving
livestock is a challenge, especially against economic,
environmental and regulatory headwinds. We make it our mission to
find new and novel ways to support our stakeholders and the
industry."
Dan Rosmarin, VP, Commercial,
at Ginkgo Bioworks: "Partnering with NOVUS presents an exciting
opportunity to apply Ginkgo's enzyme development services in a very
important domain. Together, we can accelerate the development of
innovative products that offer tangible benefits to the animal
agriculture industry, with the potential to enhance both
productivity and sustainability. This partnership will leverage
Ginkgo's research innovation platform combined with NOVUS's animal
feed application knowledge, putting us on the path to create
innovative technologies that meet the evolving needs of the
livestock industry. We are very excited to see scientific progress
already made on this project at Ginkgo and appreciate the
opportunity to contribute to NOVUS's next generation of innovative
feed additives."
To learn more about how you can bring innovative biological
solutions to life, read more at Ginkgo Enzyme Services.
About Ginkgo Bioworks
Ginkgo Bioworks is the leading
horizontal platform for cell programming, providing flexible,
end-to-end services that solve challenges for organizations across
diverse markets, from food and agriculture to pharmaceuticals to
industrial and specialty chemicals. Ginkgo Biosecurity is building
and deploying the next-generation infrastructure and technologies
that global leaders need to predict, detect, and respond to a wide
variety of biological threats. For more information, visit
ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or
follow us on social media channels such as X (@Ginkgo and
@Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads
(@GinkgoBioworks), or LinkedIn.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
About NOVUS
NOVUS is the intelligent nutrition company
providing solutions for the animal agriculture industry around the
world. The company's portfolio includes trace minerals, nutritional
enzymes, feed digestibility and meat quality solutions, and
methionine supplementation products, as well as a network of
experts globally who provide guidance on management best practices.
To learn how NOVUS is Made of More™, visit novusint.com.
NOVUS MEDIA CONTACT
Elizabeth.Davis@novusint.com
Forward-Looking Statements of Ginkgo Bioworks
This
press release contains certain forward-looking statements within
the meaning of the federal securities laws, including statements
regarding the capabilities and potential success of the partnership
and Ginkgo's cell programming platform. These forward-looking
statements generally are identified by the words "believe," "can,"
"project," "potential," "expect," "anticipate," "estimate,"
"intend," "strategy," "future," "opportunity," "plan," "may,"
"should," "will," "would," "will be," "will continue," "will likely
result," and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) volatility in the price of Ginkgo's securities due
to a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, and changes
in laws and regulations affecting Ginkgo's business, (ii) the
ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional business
opportunities, (iii) the risk of downturns in demand for products
using synthetic biology, (iv) the uncertainty regarding the demand
for passive monitoring programs and biosecurity services, (v)
changes to the biosecurity industry, including due to advancements
in technology, emerging competition and evolution in industry
demands, standards and regulations, (vi) the outcome of any pending
or potential legal proceedings against Ginkgo, (vii) our ability to
realize the expected benefits from and the success of our Foundry
platform programs, (viii) our ability to successfully develop
engineered cells, bioprocesses, data packages or other
deliverables, and (ix) the product development or commercialization
success of our customers. The foregoing list of factors is not
exhaustive. You should carefully consider the foregoing factors and
the other risks and uncertainties described in the "Risk Factors"
section of Ginkgo's annual report on Form 10-K filed with the U.S.
Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly
report on Form 10-Q, and other documents filed by Ginkgo from time
to time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novus-leverages-ginkgo-bioworks-to-develop-innovative-feed-additives-for-animal-agriculture-302256371.html
SOURCE Ginkgo Bioworks